Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
piggyBac CD19 CAR T cells
- Development stage
- Unknown
- Lead developer
- Nagoya University
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
piggyBac CD19 CAR T cells are an autologous, non-viral chimeric antigen receptor (CAR) T-cell therapy targeting the CD19 antigen. Unlike conventional CAR T-cell products that typically utilize lentiviral or retroviral vectors for gene delivery, this therapy employs the piggyBac transposon system. This system uses electroporation to introduce DNA plasmids (transposon and transposase) into T cells, allowing for the stable integration of the CAR transgene into the host genome. This non-viral approach is hypothesized to reduce manufacturing costs and complexity while potentially offering a safer profile regarding insertional mutagenesis. The therapy is primarily being developed for the treatment of relapsed or refractory CD19-positive B-cell malignancies, including various subtypes of non-Hodgkin lymphoma such as diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma.
- Other names
- piggyBac-mediated CD19-directed CAR T cellsautologous piggyBac transposon-mediated CD19-directed CAR T cells
02
Targets
Beyond the preview
Go deeper on piggyBac CD19 CAR T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on piggyBac CD19 CAR T cells.